Wednesday, December 20, 2023 6:08:48 PM
By the way, I believe that what's making DCVax-L work so well is the increase in T-cells at the tumor site. The question that hasn't yet been answered is whether this phenomena is only occurring in GBM, or if it's known to be the case in the patients with other cancers who've received DCVax-L under compassionate use. I don't know if any data exists, or if it was determined so late in the GBM trial that no attempt has been made to get that data, but if it's known to be the case, it's a solid reason for a tumor agnostic label.
Aspirin has been marketed for over a century and they keep finding new benefits from using it. I believe that DCVax-L could be much the same. I can't say it benefits Alzheimer's patients, but if it did, getting cancer to cure it is hardly a desirable way to treat it. The question might be, can DCVax-Direct be made and of benefit even if there isn't a solid tumor to inject it into. I certainly don't know, but I believe if T-cell production is somehow spurred by both of the DCVax's, that by itself may make them miracle drugs against all sorts of diseases, not just cancer. I certainly don't know that this is the case, but I don't know that T-cells were even being looked into in patients until Dr. Bosch did so, apparently well after the trial ended because if it had been earlier, I believe his findings could have been included in the Journal. As I remember it, he was one of the authors.
As I said when I saw his presentation is that the Journal explained how well DCVax-L worked, but it was Dr. Bosch's presentation that explained at least in part why it was working. Increased T-cells may not be the only reason, but they are certainly one of the reasons, and they may be of benefit in far more than GBM, or even cancer in general. Perhaps even blood borne cancers, like leukemia, could benefit from DCVax-Direct administered into the bloodstream.
Hopefully everyone knows I'm not a medical expert, but I do like to stir the pot and see what the experts think.
Gary
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM